Vølund, Aage

Interleukin-1-receptor antagonist in type 2 diabetes mellitus

Larsen, C. M., Faulenbach, M., Vaag, A., Vølund, A., Ehses, J. A., Seifert, B., Mandrup-Poulsen, T., & Donath, M. Y. (2007) · New England Journal of Medicine

Pancreatic function and diabetesDiabetes Treatment and Management

Cited by 1,798

The Influence of GLP-1 on Glucose-Stimulated Insulin Secretion

Kjems, L. L., Holst, J. J., Vølund, A., & Madsbad, S. (2003) · Diabetes

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 582

Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus

Vilsbøll, T., Krarup, T., Sonne, J., Madsbad, S., Vølund, A., Juul, A. G., & Holst, J. J. (2003) · The Journal of Clinical Endocrinology & Metabolism

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 528

Reduced Incretin Effect in Type 2 Diabetes

Knop, F. K., Vilsbøll, T., Højberg, P. V., Larsen, S., Madsbad, S., Vølund, A., Holst, J. J., & Krarup, T. (2007) · Diabetes

Pancreatic function and diabetesDiabetes Treatment and Management

Cited by 349

Near normalisation of blood glucose improves the potentiating effect of GLP-1 on glucose-induced insulin secretion in patients with type 2 diabetes

Højberg, P. V., Zander, M., Vilsbøll, T., Knop, F. K., Krarup, T., Vølund, A., Holst, J. J., & Madsbad, S. (2008) · Diabetologia

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 89